Treating to target with etanercept in rheumatoid arthritis: cost-effectiveness of dose reductions when remission is achieved.
(2014) In Value in Health 17(5). p.537-544- Abstract
- Current management of rheumatoid arthritis (RA) focuses on inducing remission as early as possible to avoid lasting joint damage, and maintenance of remission has become important. A 12-month clinical trial in 834 patients with moderate RA investigated whether etanercept 50 mg/wk could be reduced to half dose or discontinued in patients who achieved low disease activity after 36 weeks.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4614514
- author
- Kobelt, Gisela LU
- organization
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Value in Health
- volume
- 17
- issue
- 5
- pages
- 537 - 544
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:25128046
- wos:000341084700007
- scopus:84906273443
- pmid:25128046
- ISSN
- 1098-3015
- DOI
- 10.1016/j.jval.2014.04.005
- language
- English
- LU publication?
- yes
- id
- 1d31cc88-c168-4275-a800-4fb2e7fff73f (old id 4614514)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25128046?dopt=Abstract
- date added to LUP
- 2016-04-01 11:13:13
- date last changed
- 2022-03-12 20:43:51
@article{1d31cc88-c168-4275-a800-4fb2e7fff73f, abstract = {{Current management of rheumatoid arthritis (RA) focuses on inducing remission as early as possible to avoid lasting joint damage, and maintenance of remission has become important. A 12-month clinical trial in 834 patients with moderate RA investigated whether etanercept 50 mg/wk could be reduced to half dose or discontinued in patients who achieved low disease activity after 36 weeks.}}, author = {{Kobelt, Gisela}}, issn = {{1098-3015}}, language = {{eng}}, number = {{5}}, pages = {{537--544}}, publisher = {{Wiley-Blackwell}}, series = {{Value in Health}}, title = {{Treating to target with etanercept in rheumatoid arthritis: cost-effectiveness of dose reductions when remission is achieved.}}, url = {{http://dx.doi.org/10.1016/j.jval.2014.04.005}}, doi = {{10.1016/j.jval.2014.04.005}}, volume = {{17}}, year = {{2014}}, }